There is one clinical trial.
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety and reactogenicity of a single dose level of mRNA-1273 vaccine administered in 2 doses 28 days apart to an adolescent population.
Description: Acceptable serum Ab threshold as predefined for the study.Measure: Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57 Time: Day 57 (28 days after second dose)
Description: Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.Measure: Number of Participants with a SARS-CoV-2 Infection Starting on Day 57 Time: Day 57 up to Day 394
Description: Clinical signs indicative of COVID-19 as predefined for the study.Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 394 (1 year after second dose)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports